Table 4.
Association of serum PDGF-BB and Prolactin levels (in ng/ml) with clinical parameters
| PDGF-BB(ng/ml) | Prolactin(ng/ml) | |
|---|---|---|
| Disease: |
|
|
| PSP/CBS (n = 38) a |
8.7 (2.7-12.6) |
3.4 (0.3-41.2) |
| MSA (n = 31) a |
8.4 (2.9-11.6) |
3.3 (0.1-74.1) |
| PD (n = 117) a |
6.9 (3.0-12.7) |
2.3 (0.0-35.1) |
| Controls (n = 99) a |
5.9 (2.0-10.8) |
3.7 (0.5-37.5) |
| |
p = 4x10-7 b |
p = 3x10-7 b |
| Females (n = 132) a |
6.7 (2.4-12.7) |
3.1 (0.0-74.1) |
| Males (n = 153) a |
6.8 (2.0-12.0) |
3.3 (0.0-37.4) |
| |
p = ns c |
p = ns c |
| Age, y |
R = 0.006 |
R = −0.040 |
| |
p = ns d |
p = ns d |
| Duration, y |
R = −0.183 |
R = −0.226 |
| |
p = ns d |
p = ns d |
| Hoehn&Yahr |
R = 0.105 |
R = 0.217 |
| |
p = ns e |
p = 0.02 e |
| Dementia (n = 31) a |
8.3 (4.2-12.6) |
3.1 (0.0-35.1) |
| No Dementia (n = 148) a |
7.1 (2.6-12.7) |
2.7 (0.0-74.1) |
| |
p = 0.038 c |
p = ns c |
| Parkinson treatment: |
|
|
| None (n = 48) a |
6.5 (2.0-12.7) |
3.6 (0.2-37.5) |
| LD (n = 48) a |
7.4 (2.7-12.6) |
4.0 (0.0-74.1) |
| DA (n = 8) a |
6.6 (3.7-8.6) |
0.0 (0.0-3.1) |
| MAO-B Inh. (n = 8) a |
8.1 (5.5-11.4) |
2.8 (1.7-4.7) |
| LD + DA (n = 48) a |
6.1 (2.9-11.4) |
0.2 (0.0-33.2) |
| LD + MAO-B Inh. (n = 12) a |
10.3 (5.0-11.7) |
9.4 (0.3-41.2) |
| LD + DA + MAO-B Inh. (n = 7) a |
6.9 (5.6-10.4) |
0.3 (0.0-19.9) |
| p = 0.002 b | p = 7x10-13 b |
a Data are shown as median (range). Associations were statistically analyzed by b Kruskal Wallis test, c Mann–Whitney U tests, d linear regressions and e Spearman’s correlations. P-values were corrected for 7 comparisons by Bonferroni’s correction for multiple comparisons.
Abbreviations: ns = not statistically significant, R = correlation coefficient, LD = patients treated with levodopa, DA = patients treated with dopmaine agonists, MAO-B Inh. = patients treated with monoamine oxidase inhibitors.